Objectives: Outbreaks caused by linezolid-resistant (LR) enterococci remain rare. We report the epidemiological and molecular characteristics of the multiclonal dissemination of LR enterococci in the intensive care unit (ICU) of a Greek hospital.
Introduction
Infections due to vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE) commonly necessitate the use of linezolid for their treatment. 1 Although initial studies suggested that resistance to linezolid would be slow to develop, 2 linezolid-resistant (LR) enterococci emerged soon after its clinical introduction. 3, 4 The linezolid resistance mechanism among clinical enterococci has up to now been mainly attributed to the G2576T mutation in the 23S rRNA gene. 2, 5 Despite the widespread hospital use of linezolid, LR enterococcal isolates still seem to be very rare, remaining essentially undetectable in large-scale epidemiological surveys, 6 including in large VRE collections from Europe. 7 Similarly, linezolid resistance remains rare among E. faecalis and E. faecium clinical isolates in Greek hospitals. 8 In the literature, the emergence of LR enterococci has been mostly documented from individual cases or small series. 3, 4, 9 Only a few studies have reported outbreaks of clinical infections due to LR enterococci and these either described clonal spread of the isolates 10, 11 or did not analyse their clonal relationship. 12 In our hospital, an LR E. faecium clinical isolate was first recovered from blood cultures of a patient hospitalized in the intensive care unit (ICU) during 2004. 13 Preliminary susceptibility data in our hospital indicate that LR enterococci have been increasingly isolated in our ICU since late 2006, when we started monitoring linezolid resistance. We report herein the multiclonal spread of LR E. faecium and E. faecalis in our ICU during 2007-08.
Materials and methods

Hospital setting and bacterial collection
The study included LR E. faecalis and E. faecium isolates (linezolid MICs ≥8 mg/L) 14 recovered from clinical infection samples of patients hospitalized from January 2007 to October 2008 in the ICU of the University Hospital of Larissa, Greece, which has 600 beds and an ICU with a 12 bed general ward and an 8 bed cardiothoracic surgical ward. LR enterococci were also recovered from rectal samples collected during the routine surveillance of ICU patients for VRE. The isolates were stored at 2808C before testing.
Phenotypic testing
Identification of isolates to the species level was confirmed using conventional biochemical tests 14 and API 20 Strep (bioMérieux, Marcy l'Étoile, France). Susceptibility testing was performed by disc diffusion, 15 and MICs of linezolid, teicoplanin, quinupristin/dalfopristin and vancomycin by Etest (AB Biodisk, Solna, Sweden). Linezolid MICs were additionally determined by agar dilution, 15 with 2 mg/L increments for concentrations 2 -32 mg/L and using a final inoculum of 10 4 cfu/spot. E. faecalis ATCC 29212 was used as the control in phenotypic assays.
PCR assays and DNA sequencing
Mutations conferring linezolid resistance were sought by PCR, using four overlapping primers designed for this study to amplify the entire 23S rRNA gene:
′ and 4-Rev, 5 ′ -CGATTAGTATTGGTCCGCTC-3 ′ (1988-2896). The primers were designed using Oligo Explorer 1.2 (Gene Link, Hawthorne, NY, USA) and had 100% identity with the 23S rDNA of E. faecalis V583 and E. faecium LMG 11423 (accession numbers NC_004668 and AJ295305, respectively). Both strands of the amplicons were sequenced.
Macrorestriction analysis
PFGE of the LR E. faecium and E. faecalis isolates was performed with CHEF-DRIII (Bio-Rad, Hemel Hempstead, UK), with a running time of 18 h and pulse times of 5 -35 s. PFGE patterns were compared visually and by using Fingerprinting II Software version 3.0 (Bio-Rad Laboratories, Inc., USA).
Review of patients' data
Medical records of patients that harboured LR enterococci were examined to ascertain factors that may have influenced resistance development and the spread of isolates. The hospital location of patients, anonymized demographic data, clinical characteristics and prior exposure to linezolid for ≥3 days were abstracted.
Results
LR enterococcal isolates and patients' characteristics
During the study period, 17 LR E. faecium and 5 LR E. faecalis isolates were recovered from 16 separate patients hospitalized in the ICU wards. The characteristics of the patients and their isolates are presented in Table 1 . Isolates were recovered from clinical infection samples of nine patients and rectal samples of seven patients, while two patients (Patients 9 and 11; Table 1) yielded LR E. faecium isolates from both clinical and rectal samples. Clinical specimens included blood (seven isolates), pus (three isolates), and one isolate each from vascular catheter and trauma. A single LR isolate was recovered from 11 patients, two LR isolates from 4 patients and three LR isolates from 1 patient. One patient yielded LR E. faecium from a rectal sample and soon thereafter LR E. faecalis from blood cultures (Patient 6; Table 1 ).
Nine of the 16 study patients (56.3%) had evidence of clinical infection due to LR enterococci. The crude mortality rate was 18.8%. The patients had acquired the LR enterococci during hospitalization, since all were hospitalized for ≥10 days prior to the recovery of the organism; most of them had significant comorbidities (Table 1) . One patient, who yielded the LR isolate belonging to PFGE type VI, was hospitalized in a neighbouring hospital before being transferred to our ICU, 12 days prior to the LR isolation. Most patients received multiple antimicrobials prior to the recovery of LR isolates. Only nine patients had received linezolid for ≥3 days prior to the isolation of an LR enterococcal isolate. 
Antimicrobial susceptibility profiles
PFGE typing
PFGE analysis of the 17 E. faecium isolates showed seven unrelated genotypes (types I -VII), while three unrelated genotypes (types VIII -X) were identified among the 5 E. faecalis isolates (Table 1 and Figure 1 ). PFGE types I and VIII contained two subtypes each. PFGE type I was the most common, being detected in seven E. faecium from four separate patients (Table 1) . LR E. faecium isolates of PFGE subtype Ia were recovered from two patients with prolonged linezolid administration prior to the LR isolation and from one patient not exposed to linezolid, while subtype Ib was recovered from a patient not given linezolid. E. faecalis of subtype VIIIa was recovered from a patient that had received linezolid for 15 days, in contrast to subtype VIIIb, which was recovered from two patients not exposed to linezolid. The LR E. faecium isolates that were isolated from both clinical and surveillance samples from the same patient were indistinguishable.
Sequence analysis
Sequencing of the overlapping PCR products showed G2576T as the sole mutation across the entire 23S rRNA gene in all isolates. A careful examination of the sequencing traces revealed both mutated and non-mutated 23S rRNA gene copies in 12 isolates, with the mutated T being the predominant base called by the sequencer ( Figure S1 , available as Supplementary data at JAC Online). In 10 isolates the mutated trace was homogeneous. 
Discussion
LR enterococci remain uncommon. 6, 7 The present study describes the spread of several clones of LR E. faecalis and LR E. faecium during a 2 year period in our ICU. In the literature, studies reporting the dissemination of LR enterococci are limited and document clonally related isolates, 10, 11 in contrast with our study which detected multiple clones. In particular, one report described a clonal outbreak of LR E. faecium in a US medical centre that affected 40 hospitalized patients; it is of note that only 15% of the patients received linezolid before yielding LR isolates. 10 Also, a clonal outbreak involved 12 indistinguishable LR E. faecalis isolates in the ICU and reanimation unit of a Spanish hospital. 11 In Greece, where multidrug resistance is increasing, 16 linezolid resistance remains rare and there is only one study reporting five LR enterococci colonizing patients in a single ward, with four of the isolates being clonally related. 17 The present survey reports 22 LR enterococci that disseminated in the ICU of our hospital. The multiclonal composition of the LR isolates indicates that linezolid resistance emerged on several independent occasions and patient-to-patient transmission was not the main route of dissemination.
The majority of our patients had multiple risk factors for colonization and/or infection with multidrug-resistant bacteria, and prior exposure to antibiotics. Several of them had not received linezolid; they possibly acquired the LR isolate from another patient or, alternatively, the mutation may have occurred independently. It should be noted that the increased isolation of LR enterococci in the ICU led to the reinforcement of infection control measures and more rational use of linezolid, after which the recovery of such isolates became very uncommon.
Linezolid resistance is usually selected in vivo by prolonged drug treatment or inappropriate linezolid dosage. 18 Most of the reported clinical resistant mutants carry the G2576T mutation. 2, 5 As most bacteria contain four to six 23S rRNA gene copies, multiple copies must be mutated to confer resistance, 8 which possibly accounts for the rarity of resistance. 6, 7 In our study, all isolates bore only the G2576T mutation, despite having sequenced the entire 23S rRNA gene. In 10 isolates the mutated sequencing trace at nt position 2576 was homogeneous, indicating that all 23S rRNA gene copies were mutated, while in the remaining 12 heterogeneous isolates, the trace corresponding to the mutated T was predominant relative to the non-mutated trace.
The emergence of linezolid resistance amongst enterococci, be it as a result of patient-to-patient transmission or selective pressure, is of concern. Tracking or restricting linezolid use according to therapeutic indications might reduce the emergence of LR enterococci. Also, risk factors, such as prior antibiotic administration or underlying diseases, should be taken into consideration and susceptibility testing of clinically significant Grampositive pathogens should be performed before commencing treatment with linezolid, to help prevent treatment failure.
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